PMID-11673763 – AOD9604 Fat Oxidation and Weight Loss in Obese Mice
Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449.
Quick Reference
| Property | Value |
|---|---|
| PMID | 11673763 |
| DOI | 10.1038/sj.ijo.0801740 |
| Year | 2001 |
| Journal | International Journal of Obesity |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | ob/ob mice, 14-day treatment protocol |
| Peptide(s) Studied | AOD-9604 |
Key Findings
- 14-day chronic treatment with AOD9604 significantly reduced body weight gain in obese (ob/ob) mice
- AOD9604 increased fat oxidation and stimulated lipolysis in adipose tissue
- Critically, AOD9604 does NOT interact with the human growth hormone receptor — its mechanism of action is entirely distinct from full-length GH
- No effect on food intake was observed, indicating the weight loss was driven by metabolic changes rather than appetite suppression
- AOD9604 effects were comparable to full-length hGH in terms of fat reduction but without the growth-promoting or diabetogenic side effects
Study Design
ob/ob mice received daily intraperitoneal injections of AOD9604 or hGH for 14 days. Body weight, food intake, fat oxidation (via indirect calorimetry), and lipolysis markers were measured. GH receptor binding assays were performed to assess whether AOD9604 signals through the classical GH pathway.
Limitations
- ob/ob mice lack leptin entirely, representing an extreme genetic obesity model with limited translatability
- 14-day treatment period is relatively short for assessing sustained weight management
- Intraperitoneal route used rather than the clinically relevant oral or subcutaneous routes
- No dose-response relationship established
Clinical Relevance
This study provided the critical mechanistic insight that AOD9604 operates independently of the GH receptor. This finding is clinically significant because it means AOD9604 can promote fat loss without the risks associated with GH therapy (insulin resistance, IGF-1 elevation, fluid retention). The novel mechanism also suggests potential for combination with other metabolic therapies without GH axis interference.
Related
#research #animal-in-vivo #AOD-9604 #evidence-level-V